| Name | Title | Contact Details |
|---|
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.